Across 559 plasma samples spanning 24 cancer types and clinically relevant tumor fractions, APEX outperforms existing approaches for individual-gene inference, resolves pancreatic cancer transcriptional subtypes, tracks therapeutic targets in small-cell lung cancer, and identifies NECTIN4 expression as a biomarker of r...
G. Gulati, D. Vasseur, R. Nawfal et al.· Research Square· 0 citations
PURPOSE Prognostic biomarkers that estimate residual recurrence risk after standard adjuvant therapy to guide further treatment escalation are an unmet clinical need. This study used Ataraxis Breast CTX, a causal multi-modal AI model integrating clinical variables and histopathology, to stratify residual risk in clinic...
T. Bachelot, S. Chabaud, J. Lemonnier et al.· medRxiv· 1 citation
The model generated treatment-specific recurrence probabilities for each patient, with near-perfect calibration and strong prognostic discrimination across both 5- and 10-year follow-up horizons, and out-performed existing recurrence-score-based tests.
D. Biswas, Jeroen Berrevoets, A. McClean et al.· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.